Regulation of dopaminergic neural transmission by tyrosine hydroxylase protein at nerve terminals

  • Sumi-Ichinose Chiho
    Department of Pharmacology, School of Medicine, Fujita Health University, Japan
  • Ichinose Hiroshi
    Department of Life Science, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Japan
  • Ikemoto Kazuhisa
    Department of Pharmacology, School of Medicine, Fujita Health University, Japan
  • Nomura Takahide
    Department of Pharmacology, School of Medicine, Fujita Health University, Japan
  • Kondo Kazunao
    Department of Pharmacology, School of Medicine, Fujita Health University, Japan

書誌事項

タイトル別名
  • Advanced Research on Dopamine Signaling to Develop Drugs for the Treatment of Mental Disorders: Regulation of Dopaminergic Neural Transmission by Tyrosine Hydroxylase Protein at Nerve Terminals

この論文をさがす

抄録

5R-L-Erythro-5,6,7,8-tetrahydrobiopterin (BH4) is an essential cofactor for tyrosine hydroxylase (TH). Recently, a type of dopa-responsive dystonia (DRD) (DYT5, Segawa’s disease) was revealed to be caused by dominant mutations of the gene encoding GTP cyclohydrolase I (GCHI), which is the rate-limiting enzyme of BH4 biosynthesis. In order to probe the role of BH4 in vivo, we established BH4-depleted mice by disrupting the 6-pyruvoyltetrahydropterin synthase (PTS) gene (Pts−/−) and rescued them by introducing human PTS cDNA under the control of the human dopamine β-hydroxylase (DBH) promoter (Pts−/−-DPS). The Pts−/−-DPS mice developed hyperphenylalaninemia. Interestingly, tyrosine hydroxylase protein was dramatically reduced in the dopaminergic nerve terminals of these mice, and they developed abnormal posture and motor disturbance. We propose that the biochemical and pathologic changes of Pts−/−-DPS mice are caused by mechanisms common to human DRD, and understanding these mechanisms could give us insight into other movement disorders.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (69)*注記

もっと見る

詳細情報

問題の指摘

ページトップへ